Literature DB >> 30488642

Aluminum granuloma in a child secondary to DTaP-IPV vaccination: A case report.

Carter K Haag1, Elizabeth Dacey2, Nick Hamilton3, Kevin P White1.   

Abstract

Reports detailing the acute formation of aluminum granulomas, which can cause persistent, intensely pruritic nodules secondary to the administration of aluminum-containing vaccines, are infrequently described in medical literature. To our knowledge, this is the first report describing the development of an aluminum granuloma causing a persistent, pruritic nodule at the injection site following the administration of the DTaP-IPV vaccine. We present the case of a 6-year-old girl who developed a severely pruritic subcutaneous nodule on her anterior right thigh at the injection site three weeks after the administration of the aluminum-containing DTaP-IPV (Kinrix) vaccine. The nodule was eventually excised 14 months after its initial appearance, after which her symptoms resolved. Histologic inspection demonstrated a dense, deep dermal and subcutaneous nodular mixed infiltrate of lymphocytes, histiocytes, and eosinophils, with germinal center formation. The bluish, amphophilic granular cytoplasm found in most of the histiocytes is a characteristic feature of "aluminum granulomas." This adverse reaction should be considered in any patient presenting with similar findings in the weeks following a DTaP-IPV vaccination or other aluminum-containing vaccines. Furthermore, the self-limiting tendency of these nodules should not preclude affected patients from any future vaccinations, though vaccines without aluminum should be preferentially selected when possible.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  aluminum granuloma; dermatopathology; pediatric dermatology; subcutaneous nodule; vaccine site reactions; vaccines

Mesh:

Substances:

Year:  2018        PMID: 30488642     DOI: 10.1111/pde.13732

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  2 in total

1.  An injectable excipient prevents anti-polyethylene glycol antibody-mediated hypersensitivity.

Authors:  Yiwei Liu; Colton A Smith; Monique Payton; David Jenkins; Laura J Janke; Mary V Relling
Journal:  Allergy       Date:  2021-05-29       Impact factor: 14.710

2.  Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture.

Authors:  Mikhail F Vorovitch; Karina G Grishina; Viktor P Volok; Liubov L Chernokhaeva; Konstantin V Grishin; Galina G Karganova; Aidar A Ishmukhametov
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.